On October 2, 2023, the Board of Directors of FibroGen, Inc. appointed Interim Chief Executive Officer Thane Wettig as a member of the Board. Mr. Wettig was appointed as a Class I director for the term expiring at the Company?s 2024 annual meeting of stockholders. Mr. Wettig held the position of Interim Chief Executive Officer since July 23, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.2 USD | +4.35% | -7.69% | +35.39% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.39% | 119M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- FGEN Stock
- News FibroGen, Inc.
- FibroGen, Inc. Appoints Thane Wettig as a Member of the Board